Clinical Trials Browser

Recruiting × Fluorodeoxyglucose F18 × Gynecologic × Clear all

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06503146 2026-03-27

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Phase 1 Recruiting

30 enrolled

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETSarcomaThoracic

Adrenal Gland Neoplasms, Anus Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Colorectal Neoplasms, Carcinoma, Medullary, Cholangiocarcinoma, Neuroendocrine Tumors, Solitary Fibrous Tumors

Clinical Trials

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers